{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:29:31Z","timestamp":1793860171075,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-T-cell depleted haploidentical hematopoietic stem cell transplantation (HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with improving patient outcomes. We have recently reported that outcomes of adult patients (pts) with ALL in complete remission (CR) receiving HaploSCT are comparable to unrelated donor transplants. We now compared HaploSCT and matched sibling donor (MSD) transplants in pts with ALL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To assess transplantation outcomes of HaploSCT and MSD transplants in pts with ALL in CR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed adult patients (\u2265\u200918\u00a0years) with ALL who underwent their first allogeneic stem cell transplantation (alloSCT) in first or second CR between 2012 and 2018, either from a T cell replete Haplo or MSD donor, and whose data were reported to the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Multivariate analysis (MVA) adjusting for differences between the groups was performed using the Cox proportional hazards regression model. Propensity score matching was also performed to reduce confounding effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis comprised 2304 patients: HaploSCT-413; MSD-1891. Median follow-up was 25\u00a0months. Median age was 37 (range 18\u201375) and 38 (18\u201376) years in HaploSCT and MSD, respectively. HaploSCT patients were transplanted more recently than those transplanted from MSD (2016 vs 2015, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). A higher rate of HaploSCT was in CR2 (33.4% vs 16.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), respectively, and fewer received myeloablative conditioning (68% vs 83.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Cytomegalovirus (CMV) seropositivity was lower in HaploSCT patients (22% vs 28%, <jats:italic>p<\/jats:italic>\u2009=\u20090.01) and donors (27.1% vs 33%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02), and a higher proportion of the HaploSCTs were performed using a bone marrow (BM) graft (46.2% vs 18.6%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The 2 groups did not differ with regard to gender, Karnofsky performance status score, ALL phenotype, Philadelphia chromosome (Ph) positivity and pre-alloSCT measurable residual disease (MRD). Graft versus host disease (GVHD) prophylaxis was mainly post-transplant cyclophosphamide (PTCy) based (92.7%) in the HaploSCT setting, while it was mostly pharmacologic in the setting of MSD (18.7% received ATG). Cumulative incidence of engraftment at day 60 was higher in MSD transplants compared to HaploSCT (98.7% vs 96.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), respectively. Day 180 incidence of acute (a) GVHD II-IV and III-IV was higher in HaploSCT vs. MSD: 36.3% vs 28.9% (<jats:italic>p<\/jats:italic>\u2009=\u20090.002 and 15.2% vs 10.5% (<jats:italic>p<\/jats:italic>\u2009=\u20090.005), respectively. Conversely, the 2-year chronic (c) GVHD and extensive cGVHD were 32% vs 38.8% (<jats:italic>p<\/jats:italic>\u2009=\u20090.009) and 11.9% vs 19.5% (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) in HaploSCT vs MSD, respectively. Main causes of death were leukemia (31.8% vs 45%), infection (33.1% vs 19.7%) and GVHD (16.6% vs 19.7%) for HaploSCT and MSD, respectively. Two-year relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were 26% vs 31.6%, 22.9% vs 13%, 51% vs 55.4%, 58.8% vs 67.4% and 40.6% vs 39% for HaploSCT and MSD, respectively. In the MVA, RI was significantly lower in HaploSCT in comparison with MSD, hazard ratio (HR)\u2009=\u20090.66 (95% CI 0.52\u20130.83, <jats:italic>p<\/jats:italic>\u2009=\u20090.004), while NRM was significantly higher, HR\u2009=\u20091.9 (95% CI 1.43\u20132.53, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). aGVHD grade II-IV and grade III-IV were higher in HaploSCT than in MSD HR\u2009=\u20091.53 (95% CI 1.23\u20131.9, <jats:italic>p<\/jats:italic>\u2009=\u20090.0002) and HR\u2009=\u20091.54 (95% CI 1.1\u20132.15, <jats:italic>p<\/jats:italic>\u2009=\u20090.011), respectively. Extensive cGVHD was lower in HaploSCT compared with MSD, HR\u2009=\u20090.61 (95% CI 0.43\u20130.88, <jats:italic>p<\/jats:italic>\u2009=\u20090.007), while total cGVHD did not differ significantly, HR\u2009=\u20090.94 (95% CI 0.74\u20131.18, <jats:italic>p<\/jats:italic>\u2009=\u20090.58). LFS, OS and GRFS did not differ significantly between the 2 transplant groups, HR\u2009=\u20090.96 (95% CI 0.81\u20131.14, <jats:italic>p<\/jats:italic>\u2009=\u20090.66); HR\u2009=\u20091.18 (95% CI 0.96\u20131.43, <jats:italic>p<\/jats:italic>\u2009=\u20090.11) and HR\u2009=\u20090.93 (95% CI 0.79\u20131.09, <jats:italic>p<\/jats:italic>\u2009=\u20090.37), respectively. These results were confirmed in a matched-pair analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Outcomes of adult patients with ALL in CR receiving alloSCT from haploidentical donors are not significantly different from those receiving transplants from MSD in terms of LFS, OS and GRFS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-021-01065-7","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T16:03:07Z","timestamp":1617292987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Houhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashrafsadat","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose-Marie","family":"Hamladji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Al Zahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Arat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"G\u00fclbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Henri","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Canaani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"1065_CR1","doi-asserted-by":"crossref","unstructured":"Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339\u201348.","DOI":"10.1056\/NEJMsa1311707"},{"issue":"6","key":"1065_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/bmt.2017.34","volume":"52","author":"JR Passweg","year":"2017","unstructured":"Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","volume":"20","author":"A Di Stasi","year":"2014","unstructured":"Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20(12):1975\u201381.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"1065_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033\u201340.","journal-title":"Blood"},{"issue":"1","key":"1065_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-017-0394-2","volume":"10","author":"S Piemontese","year":"2017","unstructured":"Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrcz-Krzemien S, Santarone S, et al. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017;10(1):24.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1065_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1182\/bloodadvances.2016002386","volume":"1","author":"J Versluis","year":"2017","unstructured":"Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017;1(7):477\u201385.","journal-title":"Blood Adv"},{"issue":"9","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2015.98","volume":"29","author":"A Ruggeri","year":"2015","unstructured":"Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29(9):1891\u2013900.","journal-title":"Leukemia"},{"issue":"11","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","volume":"6","author":"R Shouval","year":"2019","unstructured":"Shouval R, Fein JA, Labopin M, Kroger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6(11):e573\u201384.","journal-title":"Lancet Haematol"},{"key":"1065_CR9","doi-asserted-by":"crossref","unstructured":"Shem-Tov N, Peczynski C, Labopin M, Itala-Remes M, Blaise D, Labussiere-Wallet H, et al. Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia. 2020;34(1):283\u201392.","DOI":"10.1038\/s41375-019-0544-3"},{"issue":"9","key":"1065_CR10","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1182\/bloodadvances.2020001499","volume":"4","author":"MM Al Malki","year":"2020","unstructured":"Al Malki MM, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A, et al. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv. 2020;4(9):2073\u201383.","journal-title":"Blood Adv"},{"issue":"25","key":"1065_CR11","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956\u201362.","journal-title":"Blood"},{"issue":"4","key":"1065_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.bbmt.2017.01.068","volume":"23","author":"J How","year":"2017","unstructured":"How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, et al. T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23(4):648\u201353.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"1065_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"D Salvatore","year":"2018","unstructured":"Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018;103(8):1317\u201328.","journal-title":"Haematologica"},{"issue":"9","key":"1065_CR14","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41409-019-0459-7","volume":"54","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia G, Boumendil A, Labopin M, Ciceri F, Tischer J, Stelljes M, et al. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed\/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2019;54(9):1499\u2013510.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"1065_CR15","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1182\/bloodadvances.2018018291","volume":"2","author":"TM Robinson","year":"2018","unstructured":"Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, et al. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018;2(11):1180\u20136.","journal-title":"Blood Adv"},{"issue":"1","key":"1065_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","volume":"13","author":"YJ Chang","year":"2020","unstructured":"Chang YJ, Wang Y, Xu LP, Zhang XH, Chen H, Chen YH, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol. 2020;13(1):27.","journal-title":"J Hematol Oncol"},{"key":"1065_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fonc.2020.00320","volume":"10","author":"SQ Li","year":"2020","unstructured":"Li SQ, Fan QZ, Xu LP, Wang Y, Zhang XH, Chen H, et al. Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL. Front Oncol. 2020;10:320.","journal-title":"Front Oncol"},{"issue":"7","key":"1065_CR18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00277-020-04080-9","volume":"99","author":"Q Chen","year":"2020","unstructured":"Chen Q, Zhao X, Fu HX, Chen YH, Zhang YY, Wang JZ, et al. Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. Ann Hematol. 2020;99(7):1643\u201353.","journal-title":"Ann Hematol"},{"issue":"1","key":"1065_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41409-020-01005-y","volume":"56","author":"A Nagler","year":"2021","unstructured":"Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2021;56(1):218\u201324.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"1065_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1065_CR21","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825\u20138."},{"key":"1065_CR22","doi-asserted-by":"crossref","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204\u201317.","DOI":"10.1016\/0002-9343(80)90380-0"},{"issue":"4","key":"1065_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610\u20131.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1065_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.0006-341X.1999.00497.x","volume":"55","author":"JP Klein","year":"1999","unstructured":"Klein JP, Pelz C, Zhang MJ. Modeling random effects for censored data by a multivariate normal regression model. Biometrics. 1999;55(2):497\u2013506.","journal-title":"Biometrics"},{"issue":"10","key":"1065_CR25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525\u201352.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"1065_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"S Giebel","year":"2019","unstructured":"Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019;54(6):798\u2013809.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1065_CR27","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41409-020-0826-4","volume":"55","author":"JR Passweg","year":"2020","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T\u2019s come into focus. Bone Marrow Transplant. 2020;55(8):1604\u201313.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1065_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-017-0480-5","volume":"10","author":"N Santoro","year":"2017","unstructured":"Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gulbas Z, et al. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017;10(1):113.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1065_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1432-2277.2011.01229.x","volume":"24","author":"Y Nannya","year":"2011","unstructured":"Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, Kurokawa M. The negative impact of female donor\/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transpl Int. 2011;24(5):469\u201376.","journal-title":"Transpl Int"},{"issue":"12","key":"1065_CR30","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1158\/1078-0432.CCR-17-3622","volume":"24","author":"F Baron","year":"2018","unstructured":"Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, et al. Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI-based regimen. Clin Cancer Res. 2018;24(12):2794\u2013803.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1065_CR31","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1038\/s41375-020-0850-9","volume":"34","author":"A Nagler","year":"2020","unstructured":"Nagler A, Dholaria B, Labopin M, Savani BN, Angelucci E, Koc Y, et al. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia. 2020;34(10):2766\u201375.","journal-title":"Leukemia"},{"issue":"3","key":"1065_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1365-2141.2005.05614.x","volume":"130","author":"JA Perez-Simon","year":"2005","unstructured":"Perez-Simon JA, Diez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol. 2005;130(3):394\u2013403.","journal-title":"Br J Haematol"},{"issue":"1","key":"1065_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bbmt.2015.09.008","volume":"22","author":"A Lazaryan","year":"2016","unstructured":"Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, et al. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. Biol Blood Marrow Transplant. 2016;22(1):134\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"1065_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/leu.2015.232","volume":"30","author":"O Ringden","year":"2016","unstructured":"Ringden O, Labopin M, Ciceri F, Velardi A, Bacigalupo A, Arcese W, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia. 2016;30(2):447\u201355.","journal-title":"Leukemia"},{"key":"1065_CR35","doi-asserted-by":"crossref","unstructured":"Nagler A, Kanate AS, Labopin M, Ciceri F, Angelucci E, Koc Y, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica. 2020.","DOI":"10.3324\/haematol.2020.247296"},{"key":"1065_CR36","doi-asserted-by":"crossref","unstructured":"Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol. 2021.","DOI":"10.1038\/s41423-020-00597-1"},{"issue":"3","key":"1065_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.seminhematol.2018.07.005","volume":"56","author":"YJ Chang","year":"2019","unstructured":"Chang YJ, Huang XJ. Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft? Semin Hematol. 2019;56(3):201\u20138.","journal-title":"Semin Hematol"},{"issue":"1","key":"1065_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-016-0321-y","volume":"9","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9(1):89.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"1065_CR39","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22(14):3467\u201376.","journal-title":"Clin Cancer Res"},{"key":"1065_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-016-0265-2","volume":"9","author":"YJ Chang","year":"2016","unstructured":"Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016;9:35.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-021-01065-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T16:20:13Z","timestamp":1617294013000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01065-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01065-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written consent to participate in the study. The study was approved by the EBMT review board and by each participating institution's local review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have none to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}